Join Anthony Costello, Medidata CEO, and David Benshoof Klein, Click Therapeutics Founder and CEO, to discuss why now is the time to embrace software-enhanced (SE) drugs.
Software-Enhanced (SE) drugs open new pipelines of opportunity, and allow forward-looking leaders to differentiate their portfolios. Be among the vanguard to understand and implement this transformative approach. Learn how you can become an expert on a topic poised to redefine patient care.
Join Anthony Costello, Medidata CEO, and David Benshoof Klein, Click Therapeutics Founder and CEO, to discuss why now is the time to embrace software-enhanced (SE) drugs.
Key takeaways:
- Leave with a better understanding of digital therapeutics and software-enhanced drugs
- How you can deliver better patient experiences and safer, more effective care
- How specific therapeutic areas like oncology and cardiometabolics can leverage SE drugs to significantly improve care
- How Click’s expertise in software-enhanced drugs, Medidata’s leading position in clinical trial technology and the combined partnership can help you innovate and boost your pipeline
Offered Free by: Medidata
See All Resources from: Medidata
